Literature DB >> 32675550

Timing But Not Patterns of Recurrence Is Different Between Node-negative and Node-positive Resected Pancreatic Cancer.

Kim C Honselmann1,2, Ilaria Pergolini1, Carlos Fernandez-Del Castillo1, Vikram Deshpande1, David Ting3, Martin S Taylor1, Louisa Bolm2, Motaz Qadan1, Ulrich Wellner2, Marta Sandini1, Dirk Bausch2, Andrew L Warshaw1, Keith D Lillemoe1, Tobias Keck2, Cristina R Ferrone1.   

Abstract

OBJECTIVE: Our aim was to evaluate recurrence patterns of surgically resected PDAC patients with negative (pN0) or positive (pN1) lymph nodes. SUMMARY BACKGROUND DATA: Pancreatic ductal adenocarcinoma (PDAC) is predicted to become the second leading cause of cancer death by 2030. This is mostly due to early local and distant metastasis, even after surgical resection. Knowledge about patterns of recurrence in different patient populations could offer new therapeutic avenues.
METHODS: Clinicopathologic data were collected for 546 patients who underwent resection of their PDAC between 2005 and 2016 from 2 tertiary university centers. Patients were divided into an upfront resection group (n = 394) and a neoadjuvant group (n = 152).
RESULTS: Tumor recurrence was significantly less common in pN0 patients as compared with pN1 patients, (upfront surgery: 55% vs. 77%, P < 0.001 and 64% vs. 78%, P = 0.040 in the neoadjuvant group). In addition, time to recurrence was significantly longer in pN0 versus pN1 patients in the upfront resected patients (median 16 mo pN0 vs. 10 mo pN1 P < 0.001), and the neoadjuvant group (pN0 21 mo vs. 11 mo pN1, P < 0.001). Of the patients who recurred, 62% presented with distant metastases (63% of pN0 and 62% of pN1, P = 0.553), 24% with local disease (27% of pN0 and 23% of pN1, P = 0.672) and 14% with synchronous local and distant disease (10% of pN0 and 15% of pN1, P = 0.292). Similarly, there was no difference in recurrence patterns between pN0 and pN1 in the neoadjuvant group, in which 68% recurred with distant metastases (76% of pN0 and 64% of pN1, P = 0.326) and 18% recurred with local disease (pN0: 22% and pN1: 15%, P = 0.435).
CONCLUSION: Time to recurrence was significantly longer for pN0 patients. However, patterns of recurrence for pN0 vs. pN1 patients were identical. Lymph node status was predictive of time to recurrence, but not location of recurrence.

Entities:  

Mesh:

Year:  2020        PMID: 32675550      PMCID: PMC6639153          DOI: 10.1097/SLA.0000000000003123

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   13.787


  18 in total

1.  Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement.

Authors:  Mark P Callery; Kenneth J Chang; Elliot K Fishman; Mark S Talamonti; L William Traverso; David C Linehan
Journal:  Ann Surg Oncol       Date:  2009-04-24       Impact factor: 5.344

2.  Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression.

Authors:  Christopher H Crane; Gauri R Varadhachary; John S Yordy; Gregg A Staerkel; Milind M Javle; Howard Safran; Waqar Haque; Bridgett D Hobbs; Sunil Krishnan; Jason B Fleming; Prajnan Das; Jeffrey E Lee; James L Abbruzzese; Robert A Wolff
Journal:  J Clin Oncol       Date:  2011-06-27       Impact factor: 44.544

3.  Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma.

Authors:  Vincent P Groot; Neda Rezaee; Wenchuan Wu; John L Cameron; Elliot K Fishman; Ralph H Hruban; Matthew J Weiss; Lei Zheng; Christopher L Wolfgang; Jin He
Journal:  Ann Surg       Date:  2018-05       Impact factor: 12.969

4.  Retrospective cohort analysis of neoadjuvant treatment and survival in resectable and borderline resectable pancreatic ductal adenocarcinoma in a high volume referral centre.

Authors:  M Itchins; J Arena; C B Nahm; J Rabindran; S Kim; E Gibbs; S Bergamin; T C Chua; A J Gill; R Maher; C Diakos; M Wong; A Mittal; G Hruby; A Kneebone; N Pavlakis; J Samra; S Clarke
Journal:  Eur J Surg Oncol       Date:  2017-06-28       Impact factor: 4.424

5.  Pancreatic ductal adenocarcinoma: long-term survival does not equal cure.

Authors:  Cristina R Ferrone; Rafael Pieretti-Vanmarcke; Jordan P Bloom; Hui Zheng; Jackye Szymonifka; Jennifer A Wargo; Sarah P Thayer; Gregory Y Lauwers; Vikram Deshpande; Mari Mino-Kenudson; Carlos Fernández-del Castillo; Keith D Lillemoe; Andrew L Warshaw
Journal:  Surgery       Date:  2012-07-03       Impact factor: 3.982

6.  N0/N1, PNL, or LNR? The effect of lymph node number on accurate survival prediction in pancreatic ductal adenocarcinoma.

Authors:  Nakul P Valsangkar; Devon M Bush; James S Michaelson; Cristina R Ferrone; Jennifer A Wargo; Keith D Lillemoe; Carlos Fernández-del Castillo; Andrew L Warshaw; Sarah P Thayer
Journal:  J Gastrointest Surg       Date:  2012-12-11       Impact factor: 3.452

7.  Prognostic factors after pancreatoduodenectomy with en bloc portal venous resection for pancreatic cancer.

Authors:  Hryhoriy Lapshyn; Peter Bronsert; Louisa Bolm; Martin Werner; Ulrich T Hopt; Frank Makowiec; Uwe A Wittel; Tobias Keck; Ulrich F Wellner; Dirk Bausch
Journal:  Langenbecks Arch Surg       Date:  2016-01-06       Impact factor: 3.445

8.  Pancreatic adenocarcinoma: the actual 5-year survivors.

Authors:  Cristina R Ferrone; Murray F Brennan; Mithat Gonen; Daniel G Coit; Yuman Fong; Sun Chung; Laura Tang; David Klimstra; Peter J Allen
Journal:  J Gastrointest Surg       Date:  2007-11-20       Impact factor: 3.452

9.  Failure patterns in resected pancreas adenocarcinoma: lack of predicted benefit to SMAD4 expression.

Authors:  Jordan M Winter; Laura H Tang; David S Klimstra; Weiguo Liu; Irena Linkov; Murray F Brennan; Michael I DʼAngelica; Ronald P DeMatteo; Yuman Fong; William R Jarnagin; Eileen M Oʼreilly; Peter J Allen
Journal:  Ann Surg       Date:  2013-08       Impact factor: 12.969

10.  The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer.

Authors:  Hartwig Riediger; Tobias Keck; Ulrich Wellner; Axel zur Hausen; Ulrich Adam; Ulrich T Hopt; Frank Makowiec
Journal:  J Gastrointest Surg       Date:  2009-05-06       Impact factor: 3.452

View more
  12 in total

1.  Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial.

Authors:  Robert P Jones; Eftychia-Eirini Psarelli; Richard Jackson; Paula Ghaneh; Christopher M Halloran; Daniel H Palmer; Fiona Campbell; Juan W Valle; Olusola Faluyi; Derek A O'Reilly; David Cunningham; Jonathan Wadsley; Suzanne Darby; Tim Meyer; Roopinder Gillmore; Alan Anthoney; Pehr Lind; Bengt Glimelius; Stephen Falk; Jakob R Izbicki; Gary William Middleton; Sebastian Cummins; Paul J Ross; Harpreet Wasan; Alec McDonald; Tom Crosby; Yuk Ting; Kinnari Patel; David Sherriff; Rubin Soomal; David Borg; Sharmila Sothi; Pascal Hammel; Markus M Lerch; Julia Mayerle; Christine Tjaden; Oliver Strobel; Thilo Hackert; Markus W Büchler; John P Neoptolemos
Journal:  JAMA Surg       Date:  2019-11-01       Impact factor: 14.766

2.  Predictors, Patterns, and Timing of Recurrence Provide Insight into the Disease Biology of Invasive Carcinomas Arising in Association with Intraductal Papillary Mucinous Neoplasms.

Authors:  Joseph R Habib; Benedict Kinny-Köster; Neda Amini; Sami Shoucair; John L Cameron; Elizabeth D Thompson; Elliot K Fishman; Ralph H Hruban; Ammar A Javed; Jin He; Christopher L Wolfgang
Journal:  J Gastrointest Surg       Date:  2022-08-01       Impact factor: 3.267

3.  Postoperative surveillance of pancreatic ductal adenocarcinoma (PDAC) recurrence: practice pattern on standardized imaging and reporting from the society of abdominal radiology disease focus panel on PDAC.

Authors:  Linda C Chu; Zhen J Wang; Avinash Kambadakone; Elizabeth M Hecht; Jin He; Amol K Narang; Daniel A Laheru; Hina Arif-Tiwari; Priya Bhosale; Candice W Bolan; Olga R Brook; Abraham F Bezuidenhout; Richard K G Do; Samuel J Galgano; Ajit H Goenka; Alexander R Guimaraes; David M Hough; Naveen Kulkarni; Ott Le; Lyndon Luk; Lorenzo Mannelli; Michael Rosenthal; Guillermo Sangster; Zarine K Shah; Erik V Soloff; Parag P Tolat; Marc Zins; Elliot K Fishman; Eric P Tamm; Atif Zaheer
Journal:  Abdom Radiol (NY)       Date:  2022-10-14

4.  Sample-Specific Perturbation of Gene Interactions Identifies Pancreatic Cancer Subtypes.

Authors:  Ran Wei; Huihui Zhang; Jianzhong Cao; Dailei Qin; Shengping Li; Wuguo Deng
Journal:  Int J Mol Sci       Date:  2022-04-26       Impact factor: 6.208

Review 5.  Reprogramming of sentinel lymph node microenvironment during tumor metastasis.

Authors:  Yen-Liang Li; Wen-Chun Hung
Journal:  J Biomed Sci       Date:  2022-10-20       Impact factor: 12.771

6.  Postoperative hyperprogression disease of pancreatic ductal adenocarcinoma after curative resection: a retrospective cohort study.

Authors:  Siyi Zou; Xinjing Wang; Haoda Chen; Jiewei Lin; Chenlei Wen; Qian Zhan; Hao Chen; Xiongxiong Lu; Xiaxing Deng; Baiyong Shen
Journal:  BMC Cancer       Date:  2022-06-13       Impact factor: 4.638

Review 7.  Indications to total pancreatectomy for positive neck margin after partial pancreatectomy: a review of a slippery ground.

Authors:  Stefano Crippa; Giulio Belfiori; Domenico Tamburrino; Stefano Partelli; Massimo Falconi
Journal:  Updates Surg       Date:  2021-07-31

8.  Late recurrences of pancreatic cancer in patients with long-term survival after pancreaticoduodenectomy.

Authors:  Andreas Minh Luu; Orlin Belyaev; Philipp Höhn; Michael Praktiknjo; Monika Janot; Waldemar Uhl; Chris Braumann
Journal:  J Gastrointest Oncol       Date:  2021-04

9.  Evaluation of the Hamburg-Glasgow Classification in Pancreatic Cancer: Preoperative Staging by Combining Disseminated Tumor Load and Systemic Inflammation.

Authors:  Thaer S A Abdalla; Valeria Almanfalouti; Katharina Effenberger; Faik G Uzunoglu; Tarik Ghadban; Anna Dupreé; Jakob R Izbicki; Klaus Pantel; Matthias Reeh
Journal:  Cancers (Basel)       Date:  2021-11-25       Impact factor: 6.639

10.  Impact of resection margin status on survival in advanced N stage pancreatic cancer - a multi-institutional analysis.

Authors:  Christian Teske; Richard Stimpel; Marius Distler; Susanne Merkel; Robert Grützmann; Louisa Bolm; Ulrich Wellner; Tobias Keck; Daniela E Aust; Jürgen Weitz; Thilo Welsch
Journal:  Langenbecks Arch Surg       Date:  2021-03-13       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.